GlassScriptPhysician profile
Alan B Patterson
NPI 1518992346
$5,046.21
in general payments reported to CMS, 2019-2025
26 companies · $68.52 in 2025
The $68.52 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,516 · 2020: $271 · 2021: $428 · 2022: $1,984 · 2023: $582 · 2024: $197 · 2025: $68.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $1,218.62 | 2022 | |
| Abbvie INC. | $887.36 | 2019-2023 | |
| Exeltis, USA INC. | $694.24 | 2019-2022 | |
| Organon LLC | $474.54 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $339.81 | 2022-2025 | |
| Coopersurgical, INC. | $306.78 | 2022-2023 | Summit Doppler |
| Therapeuticsmd, INC. | $220.08 | 2019-2020 | |
| Amgen INC. | $122.13 | 2023-2024 | Evenity, Prolia |
| Amag Pharmaceuticals, INC. | $118.57 | 2019 | |
| Gen-Probe, INC. | $99.82 | 2019 | |
| Allergan, INC. | $84.25 | 2019-2020 | |
| Lupin INC. | $80.91 | 2019-2021 | |
| Millicent US INC | $59.64 | 2020-2025 | Intrarosa, Femring |
| Evofem Biosciences, INC. | $57.99 | 2021 | |
| Hologic Sales and Service, LLC | $45.21 | 2024-2025 | Aptima, Thinprep 2000 Processor |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mission Pharmacal Company | $41.49 | 2019 | |
| Avion Pharmaceuticals | $41.18 | 2021-2023 | Balcoltra |
| C. R. Bard, INC. & Subsidiaries | $40.52 | 2019 | |
| Astellas Pharma US INC | $34.11 | 2024 | Veozah |
| Pfizer INC. | $24.42 | 2023 | |
| Medicem INC. | $21.71 | 2022 | |
| Myovant Sciences INC. | $20.74 | 2022 | |
| Abbott Laboratories | $12.09 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.